Skip to main content
. Author manuscript; available in PMC: 2010 May 4.
Published in final edited form as: Nat Rev Neurol. 2010 Feb;6(2):108–119. doi: 10.1038/nrneurol.2009.219

Table 2.

Ongoing clinical trials of active amyloid-β immunotherapies

Therapy Sponsors Vaccine Phase and
number of trials		 Estimated
patient
enrollment		 treatment
duration		 Primary outcome
measures		 Estimated
completion date
of final trial
ACC-001 Elan; Wyeth Aβ amino-terminal
conjugate		 II; three trials 360 24 months Safety, tolerability
and treatment-related
adverse effects		 May 2012
CAD-105 Novartis Aβ1–5coupled to Qb
virus-like particles		 II; three trials 84 12–24
months		 Safety and tolerability June 2011
Affitope AD01;
Affitope AD02		 Affiris AG;
GlaxoSmithKline		 Aβ amino-terminal
mimotope ± adjuvant		 Ib; two trials 48 12 months Safety and
tolerability* 		December 2009
V950 Merck Aβ amino-terminal
peptides conjugated
to ISCO-MATRIX®‡ 		I; one trial 124 48 months Safety and tolerability April 2014
UB311 United Biochemical Aβ1–14 using UBITh®§ I; one trial 18 7 months Safety and tolerability December 2010
*

Long-term extension of previous phase I trial.

‡

ISCO-MATRIX® produced by CSL Behring, King of Prussia, PA, USA.

§

UBITh® produced by United Biomedical, Hauppauge, NY, USA. Abbreviation: Aβ, amyloid-β.